Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751563 | 1.00 | TRPA1 (0.40) | TRPA1TRPM8 | |
| SCHEMBL6758025 | 1.00 | TRPA1 (0.40) | TRPA1TRPM8 | |
| SCHEMBL6758017 | 1.00 | TRPA1 (0.40) | TRPA1TRPM8 | |
| SCHEMBL6822220 | 1.00 | TRPA1 (0.40) | TRPA1TRPM8 | |
| SCHEMBL14962550 | 0.91 | TRPA1 (0.36) | TRPA1TRPM8 | |
| SCHEMBL24921510 | 0.86 | TRPA1 (0.38) | TRPA1TRPM8 | |
| SCHEMBL15369717 | 0.86 | TRPA1 (0.38) | TRPA1TRPM8 | |
| SCHEMBL6869815 | 0.86 | TRPA1 (0.38) | TRPA1TRPM8 | |
| SCHEMBL16355176 | 0.86 | TRPA1 (0.38) | TRPA1TRPM8 | |
| SCHEMBL24226811 | 0.86 | TRPA1 (0.48) | TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-10179792-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-9302120-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9079890-B2 | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives | ARRAY BIOPHARMA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079913-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8629141-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130296303-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| US-8518984-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110251252-A1 | BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN TREATING DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179792-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | TRPA1 4854/4885TRPM8 4503/4885 |
| US-20110251252-A1 | BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN TREATING DISEASE | TP53, MDM2, FLT3 | TRPA1 4858/4885TRPM8 4713/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | TRPA1 2847/4885TRPM8 4598/4885 |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TRPA1 2963/4885TRPM8 3497/4885 |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | TRPA1 4692/4885TRPM8 4646/4885 |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | TRPA1 3605/4885TRPM8 4512/4885 |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TRPA1 2963/4885TRPM8 3497/4885 |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | TRPA1 4854/4885TRPM8 4503/4885 |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | TRPA1 3605/4885TRPM8 4512/4885 |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TRPA1 2963/4885TRPM8 3497/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | TRPA1 4727/4885TRPM8 4684/4885 |
| US-20130296303-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TRPA1 2963/4885TRPM8 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.